NO20023828D0 - Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer - Google Patents

Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer

Info

Publication number: NO20023828D0
Authority: NO; Norway
Prior art keywords: ldl; pyrimidin; derivatives; pla2 inhibitors; inhibitors
Prior art date: 2000-02-16

Application number

NO20023828A

Other languages

English (en)

Other versions

NO20023828L (no

NO324691B1 (no

Inventor

Deirdre Mary Bernadette Hickey

Robert John Ife

Colin Andrew Leach

Ivan Leo Pinto

Stephen Allan Smith

Steven James Stanway

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-16

Filing date

2002-08-13

Publication date

2002-08-13

2000-02-16 Priority claimed from GB0003636A external-priority patent/GB0003636D0/en

2001-01-19 Priority claimed from GB0101437A external-priority patent/GB0101437D0/en

2002-08-13 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2002-08-13 Publication of NO20023828D0 publication Critical patent/NO20023828D0/no

2002-09-30 Publication of NO20023828L publication Critical patent/NO20023828L/no

2007-12-03 Publication of NO324691B1 publication Critical patent/NO324691B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20023828A 2000-02-16 2002-08-13 Pyrimidin-4-on derivater, farmasoytisk sammensetning inneholdende en slik forbindelse, samt anvendelse av forbindelsene NO324691B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0003636A GB0003636D0 (en)	2000-02-16	2000-02-16	Novel compounds
GB0101437A GB0101437D0 (en)	2001-01-19	2001-01-19	Novel Compounds
PCT/EP2001/001515 WO2001060805A1 (en)	2000-02-16	2001-02-13	Pyrimidine-4-one derivatives as ldl-pla2 inhibitors

Publications (3)

Publication Number	Publication Date
NO20023828D0 true NO20023828D0 (no)	2002-08-13
NO20023828L NO20023828L (no)	2002-09-30
NO324691B1 NO324691B1 (no)	2007-12-03

Family

ID=26243663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023828A NO324691B1 (no)	2000-02-16	2002-08-13	Pyrimidin-4-on derivater, farmasoytisk sammensetning inneholdende en slik forbindelse, samt anvendelse av forbindelsene

Country Status (31)

Country	Link
US (10)	US20020103213A1 (no)
EP (2)	EP1686119B1 (no)
JP (1)	JP4095804B2 (no)
KR (1)	KR100781425B1 (no)
CN (1)	CN1179952C (no)
AR (1)	AR030190A1 (no)
AT (2)	ATE333446T1 (no)
AU (2)	AU3546601A (no)
BG (1)	BG66014B1 (no)
BR (1)	BRPI0108396B1 (no)
CA (1)	CA2400554C (no)
CO (1)	CO5271661A1 (no)
CY (2)	CY1105649T1 (no)
CZ (1)	CZ304450B6 (no)
DE (2)	DE60139429D1 (no)
DK (2)	DK1686119T3 (no)
ES (2)	ES2330552T3 (no)
GC (1)	GC0000221A (no)
HU (1)	HU229479B1 (no)
IL (2)	IL151236A (no)
MX (1)	MXPA02008062A (no)
MY (1)	MY135732A (no)
NO (1)	NO324691B1 (no)
NZ (1)	NZ520752A (no)
PL (1)	PL209824B1 (no)
PT (2)	PT1686119E (no)
SI (2)	SI1263740T1 (no)
SK (1)	SK287296B6 (no)
TW (1)	TW550259B (no)
UA (1)	UA73762C2 (no)
WO (1)	WO2001060805A1 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001060805A1 (en) *	2000-02-16	2001-08-23	Smithkline Beecham P.L.C.	Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024807D0 (en)	2000-10-10	2000-11-22	Smithkline Beecham Plc	Novel compounds
EP1326830A1 (en) *	2000-10-20	2003-07-16	Biovitrum Ab	2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
GB0119795D0 (en) *	2001-08-14	2001-10-03	Smithkline Beecham Plc	Novel process
GB0119793D0 (en) *	2001-08-14	2001-10-03	Smithkline Beecham Plc	Novel compounds
GB0127141D0 (en) *	2001-11-10	2002-01-02	Smithkline Beecham Plc	Novel compounds
GB0127139D0 (en) *	2001-11-10	2002-01-02	Smithkline Beecham	Novel compounds
GB0127143D0 (en) *	2001-11-10	2002-01-02	Smithkline Beecham	Novel compounds
GB0127140D0 (en) *	2001-11-10	2002-01-02	Smithkline Beecham	Novel compounds
EP1466904A4 (en) *	2001-12-28	2005-12-14	Takeda Pharmaceutical	BIARYL CONNECTION AND ITS USE
US6939863B2 (en)	2002-01-04	2005-09-06	Wei-Jan Chen	Prevention of atherosclerosis and restenosis
GB0208280D0 (en) *	2002-04-10	2002-05-22	Glaxo Group Ltd	Novel compounds
GB0208279D0 (en) *	2002-04-10	2002-05-22	Glaxo Group Ltd	Novel compounds
US20050227974A9 (en) *	2002-08-01	2005-10-13	Euro-Celtique S.A.	Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
JP4366122B2 (ja) *	2003-06-24	2009-11-18	日立オムロンターミナルソリューションズ株式会社	紙葉類搬送装置
GB0320522D0 (en) *	2003-09-02	2003-10-01	Glaxo Group Ltd	Formulation
AU2004291262C1 (en)	2003-11-05	2011-08-11	F. Hoffmann-La Roche Ag	Phenyl derivatives as PPAR agonists
EP2290094A1 (en)	2004-04-16	2011-03-02	Glaxo Group Limited	Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en)	2004-04-16	2015-01-15	Yaping Shou	Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
TW200608976A (en)	2004-05-08	2006-03-16	Neurogen Corp	4,5-disubstituted-2-aryl pyrimidines
DE102004061005A1 (de) *	2004-12-18	2006-06-22	Bayer Healthcare Ag	3-Cycloalkyl-1,2,4-triazin-5(2H)-one
US20080090851A1 (en) *	2006-10-13	2008-04-17	Colin Andrew Leach	Bicyclic Heteroaromatic Compounds
US7705005B2 (en) *	2006-10-13	2010-04-27	Glaxo Group Limited	Bicyclic heteroaromatic compounds
US20080090852A1 (en) *	2006-10-13	2008-04-17	Colin Andrew Leach	Bicyclic Heteroaromatic Compounds
JP5437996B2 (ja) *	2007-05-11	2014-03-12	ザトラスティーズオブザユニバーシティオブペンシルバニア	皮膚潰瘍の治療方法
BRPI0721697A2 (pt)	2007-05-11	2014-08-05	Univ Jefferson	" métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US8962633B2 (en)	2007-05-11	2015-02-24	Thomas Jefferson University	Methods of treatment and prevention of metabolic bone diseases and disorders
US8637524B2 (en)	2009-07-28	2014-01-28	Auspex Pharmaceuticals, Inc	Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
UY33388A (es) *	2010-05-17	2011-12-01	Glaxo Group Ltd	Nuevos procesos para la preparacion de compuestos de pirimidinona
EP2583099B1 (en)	2010-06-18	2016-11-02	Whitehead Institute for Biomedical Research	Pla2g16 as a target for antiviral compounds
JP2013544854A (ja) *	2010-12-06	2013-12-19	グラクソグループリミテッド	化合物
MX2013006342A (es)	2010-12-06	2013-08-26	Glaxo Group Ltd	Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
CN104478812A (zh) *	2010-12-06	2015-04-01	葛兰素集团有限公司	用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
ES2847883T3 (es)	2010-12-17	2021-08-04	Glaxo Group Ltd	Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
CN102643269B (zh) *	2011-02-21	2014-07-23	天津药物研究院	一类含吡唑结构的磷脂酶a2抑制剂及用途
WO2012122707A1 (zh) *	2011-03-16	2012-09-20	中国科学院上海药物研究所	季铵盐类化合物、其制备方法、药物组合物及用途
WO2012129792A1 (zh) *	2011-03-30	2012-10-04	中国科学院上海药物研究所	嘧啶酮类化合物、其制备方法及药物组合物和用途
EP2725024A4 (en) *	2011-06-27	2014-12-03	Shanghai Inst Materia Medica	HETEROCYCLIC AZOL COMPOUND, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
KR20140059203A (ko)	2011-07-27	2014-05-15	글락소 그룹 리미티드	2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도
CN103827116B (zh) *	2011-07-27	2016-08-31	葛兰素集团有限公司	用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物
AU2012288865B2 (en)	2011-07-27	2015-10-01	Glaxo Group Limited	Bicyclic pyrimidone compounds
CA2899124A1 (en)	2013-01-25	2014-07-31	Glaxosmithkline Intellectual Property Development Limited	Compounds
JP2016505053A (ja)	2013-01-25	2016-02-18	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
AU2014209949B2 (en)	2013-01-25	2016-09-08	Glaxosmithkline Intellectual Property Development Limited	2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors
US20140283157A1 (en)	2013-03-15	2014-09-18	Diadexus, Inc.	Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2015087239A1 (en)	2013-12-11	2015-06-18	Ranbaxy Laboratories Limited	Processes for the preparation of darapladib and its intermediates
WO2015092687A2 (en)	2013-12-17	2015-06-25	Ranbaxy Laboratories Limited	Process for the purification of darapladib
WO2015114479A1 (en)	2014-01-28	2015-08-06	Ranbaxy Laboratories Limited	Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate
WO2016012916A1 (en)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
DK3186242T3 (da)	2014-08-29	2021-12-20	Tes Pharma S R L	Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
CN105777653A (zh)	2014-12-26	2016-07-20	中国科学院上海药物研究所	用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN104840963B (zh) *	2015-05-26	2018-02-16	河北东康生物科技有限公司	含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
JP2018521021A (ja) *	2015-06-11	2018-08-02	バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａＰｈａｒｍａｃｅｕｔｉｃａＩｎｔｅｒｎａｔｉｏｎａｌＡｇ	排出ポンプ阻害剤及びその治療的使用
US10669261B2 (en) *	2015-12-16	2020-06-02	Bristl-Myers Squibb Company	Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
US10878307B2 (en) *	2016-12-23	2020-12-29	Microsoft Technology Licensing, Llc	EQ-digital conversation assistant
EP3687980B1 (en) *	2017-09-26	2022-01-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Radiolabeled darapladib, analogs thereof and their use as imaging compounds
CN110746445B (zh) *	2019-10-16	2021-03-16	深圳海关食品检验检疫技术中心	一种头孢哌酮氘代内标物的制备方法
BR112022008786A2 (pt)	2019-11-09	2022-07-26	Shanghai Simr Biotechnology Co Ltd	Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
CN115304620A (zh)	2021-05-07	2022-11-08	上海赛默罗生物科技有限公司	嘧啶酮衍生物、其制备方法、药物组合物和用途
EP4257133A1 (en)	2022-04-05	2023-10-11	Institut Pasteur	Oxo-azaheterocyclic derivatives for use in the treatment of malaria
CN119191998A (zh) *	2024-11-29	2024-12-27	浙江省质量科学研究院	一种双羟乙基氨基丙基羟乙基十六胺的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08500740A (ja)	1993-06-25	1996-01-30	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
ES2159573T3 (es) *	1993-10-06	2001-10-16	Icos Corp	Acetilhidrolasa del factor activador de plaquetas.
GB9421816D0 (en)	1994-10-29	1994-12-14	Smithkline Beecham Plc	Novel compounds
BR9510420A (pt)	1994-12-22	2004-04-20	Smithkline Beecham Plc	Azetidin-2-onas substituìdas para o tratamento de aterosclerose
CH690264A5 (fr)	1995-06-30	2000-06-30	Symphar Sa	Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
NZ311684A (en)	1995-07-01	2000-04-28	Smithkline Beecham Plc	Azetidinone derivatives, preparation, and use for treating atherosclerosis
JP2002515728A (ja)	1995-09-29	2002-05-28	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	新規用途
WO1997021676A1 (en)	1995-12-08	1997-06-19	Smithkline Beecham Plc	Azetidinone compounds for the treatment of atherosclerosis
WO1997021675A1 (en)	1995-12-08	1997-06-19	Smithkline Beecham Plc	Monocyclic beta-lactame derivatives for treatment of atherosclerosis
GB9608649D0 (en)	1996-04-26	1996-07-03	Smithkline Beecham Plc	Novel compounds
EP0915843A1 (en)	1996-04-26	1999-05-19	Smithkline Beecham Plc	Azetidinone derivatives for the treatment of atheroscleroses
GB9626536D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
GB9626615D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
GB9626616D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
DE69816471T2 (de) *	1997-11-06	2004-05-27	Smithkline Beecham P.L.C., Brentford	Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
JP2002523402A (ja) *	1998-08-21	2002-07-30	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	アテローム性動脈硬化症の治療用ピリミジノン
GB9910079D0 (en)	1999-05-01	1999-06-30	Smithkline Beecham Plc	Novel compounds
CZ20013904A3 (cs) *	1999-05-01	2002-04-17	Smithkline Beecham Plc	Pyrimidinonové sloučeniny
GB9910378D0 (en)	1999-05-05	1999-06-30	Smithkline Beecham Plc	Novel compounds
WO2001060805A1 (en) *	2000-02-16	2001-08-23	Smithkline Beecham P.L.C.	Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024808D0 (en) *	2000-10-10	2000-11-22	Smithkline Beecham Plc	Novel compounds
GB0024807D0 (en) *	2000-10-10	2000-11-22	Smithkline Beecham Plc	Novel compounds

2001
- 2001-02-13 WO PCT/EP2001/001515 patent/WO2001060805A1/en not_active Ceased
- 2001-02-13 DK DK06075890T patent/DK1686119T3/da active
- 2001-02-13 AT AT01907522T patent/ATE333446T1/de active
- 2001-02-13 ES ES06075890T patent/ES2330552T3/es not_active Expired - Lifetime
- 2001-02-13 HU HU0204410A patent/HU229479B1/hu not_active IP Right Cessation
- 2001-02-13 NZ NZ520752A patent/NZ520752A/en not_active IP Right Cessation
- 2001-02-13 PT PT06075890T patent/PT1686119E/pt unknown
- 2001-02-13 SK SK1177-2002A patent/SK287296B6/sk not_active IP Right Cessation
- 2001-02-13 AT AT06075890T patent/ATE437862T1/de active
- 2001-02-13 CA CA002400554A patent/CA2400554C/en not_active Expired - Fee Related
- 2001-02-13 DE DE60139429T patent/DE60139429D1/de not_active Expired - Lifetime
- 2001-02-13 EP EP06075890A patent/EP1686119B1/en not_active Expired - Lifetime
- 2001-02-13 AU AU3546601A patent/AU3546601A/xx active Pending
- 2001-02-13 BR BRPI0108396-1A patent/BRPI0108396B1/pt not_active IP Right Cessation
- 2001-02-13 CN CNB01806521XA patent/CN1179952C/zh not_active Expired - Fee Related
- 2001-02-13 MX MXPA02008062A patent/MXPA02008062A/es active IP Right Grant
- 2001-02-13 PT PT01907522T patent/PT1263740E/pt unknown
- 2001-02-13 KR KR1020027010662A patent/KR100781425B1/ko not_active Expired - Fee Related
- 2001-02-13 DK DK01907522T patent/DK1263740T3/da active
- 2001-02-13 CZ CZ2002-2768A patent/CZ304450B6/cs not_active IP Right Cessation
- 2001-02-13 SI SI200130614T patent/SI1263740T1/sl unknown
- 2001-02-13 PL PL357382A patent/PL209824B1/pl unknown
- 2001-02-13 ES ES01907522T patent/ES2267714T3/es not_active Expired - Lifetime
- 2001-02-13 UA UA2002097389A patent/UA73762C2/uk unknown
- 2001-02-13 EP EP01907522A patent/EP1263740B1/en not_active Expired - Lifetime
- 2001-02-13 AU AU2001235466A patent/AU2001235466B2/en not_active Ceased
- 2001-02-13 SI SI200130941T patent/SI1686119T1/sl unknown
- 2001-02-13 DE DE60121550T patent/DE60121550T2/de not_active Expired - Lifetime
- 2001-02-13 JP JP2001560190A patent/JP4095804B2/ja not_active Expired - Fee Related
- 2001-02-14 US US09/782,930 patent/US20020103213A1/en not_active Abandoned
- 2001-02-14 GC GCP20011178 patent/GC0000221A/en active
- 2001-02-14 MY MYPI20010671A patent/MY135732A/en unknown
- 2001-02-14 AR ARP010100659A patent/AR030190A1/es not_active Application Discontinuation
- 2001-02-15 TW TW090103332A patent/TW550259B/zh not_active IP Right Cessation
- 2001-02-15 CO CO01011957A patent/CO5271661A1/es active IP Right Grant
2002
- 2002-08-13 IL IL151236A patent/IL151236A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023828A patent/NO324691B1/no not_active IP Right Cessation
- 2002-08-26 BG BG107034A patent/BG66014B1/bg unknown
2003
- 2003-02-03 US US10/357,238 patent/US6649619B1/en not_active Expired - Lifetime
- 2003-10-27 US US10/694,561 patent/US7153861B2/en not_active Expired - Fee Related
2006
- 2006-10-06 CY CY20061101441T patent/CY1105649T1/el unknown
- 2006-11-17 US US11/561,035 patent/US7470694B2/en not_active Expired - Fee Related
- 2006-11-21 US US11/561,926 patent/US7638520B2/en not_active Expired - Fee Related
2007
- 2007-03-15 IL IL181957A patent/IL181957A0/en unknown
2009
- 2009-01-06 US US12/349,086 patent/US7652019B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,837 patent/US20090170877A1/en not_active Abandoned
- 2009-10-12 CY CY20091101045T patent/CY1109484T1/el unknown
2010
- 2010-02-18 US US12/707,838 patent/US20100144765A1/en not_active Abandoned
2011
- 2011-12-02 US US13/309,941 patent/US8871775B2/en not_active Expired - Fee Related
2014
- 2014-10-24 US US14/522,870 patent/US9266841B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SI1263740T1 (sl)	2006-12-31
US20120172378A1 (en)	2012-07-05
IL151236A (en)	2009-02-11
BG66014B1 (bg)	2010-10-29
PT1263740E (pt)	2006-11-30
DK1686119T3 (da)	2009-11-09
JP4095804B2 (ja)	2008-06-04
PL209824B1 (pl)	2011-10-31
US20150045375A1 (en)	2015-02-12
ATE437862T1 (de)	2009-08-15
US20090170877A1 (en)	2009-07-02
US7153861B2 (en)	2006-12-26
DE60121550D1 (de)	2006-08-31
ES2330552T3 (es)	2009-12-11
US20070123549A1 (en)	2007-05-31
CZ304450B6 (cs)	2014-05-14
GC0000221A (en)	2006-03-29
NO20023828L (no)	2002-09-30
TW550259B (en)	2003-09-01
AU2001235466B2 (en)	2004-04-22
MXPA02008062A (es)	2002-11-29
US8871775B2 (en)	2014-10-28
US20020103213A1 (en)	2002-08-01
CN1179952C (zh)	2004-12-15
SK11772002A3 (sk)	2003-02-04
JP2003523335A (ja)	2003-08-05
HUP0204410A3 (en)	2003-07-28
DE60121550T2 (de)	2007-06-21
US7470694B2 (en)	2008-12-30
CO5271661A1 (es)	2003-04-30
HK1053466A1 (en)	2003-10-24
MY135732A (en)	2008-06-30
KR20030011772A (ko)	2003-02-11
CY1109484T1 (el)	2014-08-13
US20070155762A1 (en)	2007-07-05
PL357382A1 (en)	2004-07-26
HU229479B1 (en)	2014-01-28
DE60139429D1 (de)	2009-09-10
WO2001060805A1 (en)	2001-08-23
CN1418199A (zh)	2003-05-14
DK1263740T3 (da)	2006-11-13
BG107034A (bg)	2003-04-30
IL181957A0 (en)	2009-02-11
NO324691B1 (no)	2007-12-03
BRPI0108396B1 (pt)	2015-05-19
CA2400554C (en)	2009-04-07
EP1686119A1 (en)	2006-08-02
SI1686119T1 (sl)	2009-12-31
AR030190A1 (es)	2003-08-13
NZ520752A (en)	2004-03-26
KR100781425B1 (ko)	2007-12-03
ATE333446T1 (de)	2006-08-15
EP1263740B1 (en)	2006-07-19
CY1105649T1 (el)	2010-12-22
CA2400554A1 (en)	2001-08-23
HUP0204410A2 (en)	2003-05-28
US7638520B2 (en)	2009-12-29
EP1263740A1 (en)	2002-12-11
US7652019B2 (en)	2010-01-26
ES2267714T3 (es)	2007-03-16
US20040097525A1 (en)	2004-05-20
US9266841B2 (en)	2016-02-23
US20100144765A1 (en)	2010-06-10
EP1686119B1 (en)	2009-07-29
US6649619B1 (en)	2003-11-18
AU3546601A (en)	2001-08-27
UA73762C2 (uk)	2005-09-15
US20090118313A1 (en)	2009-05-07
SK287296B6 (sk)	2010-06-07
CZ20022768A3 (cs)	2003-05-14
BR0108396A (pt)	2003-03-11
PT1686119E (pt)	2009-10-06

Publication	Publication Date	Title
NO20023828D0 (no)	2002-08-13	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
BR0010220A (pt)	2002-05-14	Compostos de pirimidinona
NO20023614L (no)	2002-09-30	Pyrimidin-karboksamider som er anvendelige som inhibitorer for PDE4-isoenzymer
DK1475377T3 (da)	2006-10-23	Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
EE200300360A (et)	2003-12-15	PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
DK1268480T3 (da)	2004-03-15	8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer
CY1112442T1 (el)	2015-12-09	Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
DK1864975T3 (da)	2011-01-24	Nikotinamid-derivater anvendelige som P38-inhibitorer
EE200300361A (et)	2003-12-15	PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid
PT1294724E (pt)	2006-07-31	Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
DK1289985T3 (da)	2004-04-05	Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20026010L (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
UY27972A1 (es)	2004-04-30	Derivados de hidantoína
NO20033288L (no)	2003-09-22	Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
WO2002085906A3 (en)	2002-12-19	Phthalazinones derivatives useful as pde4/7 inhibitors
NO20022125D0 (no)	2002-05-03	Pyrrolderivater som inhibitorer for fosfodiesterase VII
ATE384722T1 (de)	2008-02-15	Alkoxypyridinderivate
MXPA04004372A (es)	2004-08-11	Derivados heterociclicos de glicinamida y su uso medico.
NO20034434D0 (no)	2003-10-03	Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
ATE356131T1 (de)	2007-03-15	Tricyclische imidazopyridine
ATE374189T1 (de)	2007-10-15	Phthalazinon-derivate als pde 4 hemmer
NO20035206L (no)	2003-11-24	Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
WO2002067866A3 (en)	2003-05-01	Piperazine derivatives as metalloprotease inhibitors
DK0937075T3 (da)	2004-04-13	Hidtil ukendte imidazo- og oxazolopyridiner som phosphodiesteraseinhibitorer
ITMI20022739A1 (it)	2004-06-24	Derivati ftalazinici inibitori della fosfodiesterasi 4.

Legal Events

Date	Code	Title	Description
2017-09-25	MM1K	Lapsed by not paying the annual fees